Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 3/20 | 0.50 |
| ▸ | CHRNA4 | P43681 | 3/20 | 0.50 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.50 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.50 |
| ▸ | CA2 | P00918 | 2/20 | 0.48 |
| ▸ | CA12 | O43570 | 1/20 | 0.48 |
| ▸ | CA1 | P00915 | 1/20 | 0.48 |
| ▸ | CA9 | Q16790 | 1/20 | 0.48 |
| ▸ | CHKA | P35790 | 1/20 | 0.46 |
| ▸ | CHRNB3 | Q05901 | 1/20 | 0.45 |
| ▸ | CHRNA6 | Q15825 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | USP2 | O75604 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | TPSAB1 | Q15661 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6721 | 1.00 | CHRNB2 (0.50) | CHRNB2CHRNA4CHRNA3CHRNB4CA2 | |
| Ethane SCHEMBL27604108 | 0.98 | CHRNB2 (0.48) | CHRNB2CHRNA4CHRNA3CHRNB4CA2 | |
| Hydrochloric Acid SCHEMBL399052 | 0.98 | CHRNB2 (0.48) | CHRNB2CHRNA4CHRNA3CHRNB4CA2 | |
| SCHEMBL18689130 | 0.92 | CA2 (0.50) | CHRNB2CHRNA4CHRNA3CHRNB4CA2 | |
| Hydrochloric Acid SCHEMBL23778305 | 0.90 | CA2 (0.48) | CHRNB2CHRNA4CHRNA3CHRNB4CA2 | |
| Phosphoric Acid SCHEMBL29151557 | 0.90 | CHRNB2 (0.43) | CHRNB2CHRNA4CHRNA3CHRNB4CA2 | |
| SCHEMBL13935798 | 0.88 | CA2 (0.47) | CHRNB2CHRNA4CHRNA3CHRNB4CA2 | |
| Fumaric Acid SCHEMBL27690913 | 0.88 | HCAR2 (0.42) | CHRNB2CHRNA4CHRNA3CHRNB4CA2 | |
| SCHEMBL4919297 | 0.86 | — | — | |
| SCHEMBL16474061 | 0.85 | CA2 (0.47) | CHRNB2CHRNA4CHRNA3CHRNB4CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 110 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5763438-A | ANTIVIRAL AGENTS | SEIKAGAKU CORPORATION (JP) | 1998-06-09 | — | — | US | claimed |
| EP-0765865-A1 | 2-ACYLAMINOPROPANOL COMPOUND AND MEDICINAL COMPOSITION | SEIKAGAKU CORPORATION (JP) | 1997-04-02 | — | — | EP | claimed |
| US-20230414613-A1 | PHARMACEUTICAL COMPOSITIONS | Shenzhen Pharmacin Co., Ltd. (CN) | 2023-12-28 | — | — | US | disclosed |
| CN-116635015-A | Pharmaceutical composition | 深圳市药欣生物科技有限公司 | 2023-08-22 | — | — | CN | disclosed |
| EP-4221690-A1 | PHARMACEUTICAL COMPOSITIONS | Shenzhen Pharmacin Co., Ltd. (CN) | 2023-08-09 | — | — | EP | disclosed |
| EP-3984528-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING NILOTINIB | Novartis AG (CH) | 2022-04-20 | — | — | EP | disclosed |
| US-20170143716-A1 | METHOD OF TREATING PROLIFERATIVE DISORDERS AND OTHER PATHOLOGICAL CONDITIONS MEDIATED BY BCR-ABL, C-KIT, DDR1, DDR2 OR PDGF-R KINASE ACTIVITY | NOVARTIS AG (CH) | 2017-05-25 | — | — | US | disclosed |
| US-20170014468-A1 | METHODS OF USE FOR THERAPEUTICS TARGETING THE PATHOGEN PORPHYROMONAS GINGIVALIS | Cortexyme, Inc. | 2017-01-19 | — | — | US | disclosed |
| EP-2186514-B1 | Treatment of Malignant Peripheral Nerve Sheath Tumors | UNIV KINKI (JP) | 2016-06-29 | — | — | EP | disclosed |
| EP-3009128-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING NILOTINIB | Novartis AG (CH) | 2016-04-20 | — | — | EP | disclosed |
| US-9301957-B2 | Immediate release 4-methyl-3-4[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-N-[5-(4-methyl-1H-imidazol-1-YL)-3-(trifluoromethyl)phenyl] benzamide formulation | NOVARTIS AG (CH) | 2016-04-05 | — | — | US | disclosed |
| WO-2007022044-A2 | COMBINATION OF ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2007-02-22 | — | — | WO | disclosed |
| US-7169791-B2 | Inhibitors of tyrosine kinases | NOVARTIS AG (CH) | 2007-01-30 | — | — | US | disclosed |
| WO-2007010012-A2 | COMBINATION OF A PYRIMIDYLAMINOBENZAMIDE AND AN MTOR KINASE INHIBITOR | NOVARTIS AG (CH) | 2007-01-25 | — | — | WO | disclosed |
| US-20060167015-A1 | 4-Methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-N-[5-(4-methyl-1H-imidazol1yl)-3-(trifluoromethyl)phenyl]benzamide or an N-oxide or salts; anticarcinogenic agent (leukaemia) | NOVARTIS AG (CH) | 2006-07-27 | — | — | US | disclosed |
| US-6951843-B2 | Peptide derivatives and their pharmaceutically acceptable salts, thereof, processes for preparation of both and use thereof | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2005-10-04 | — | — | US | disclosed |
| EP-1333024-A1 | PEPTIDE DERIVATIVES AND THEIR PHARMACEUTICALLY ACCEPTABLE SALTS, PROCESSES FOR PREPARATION OF BOTH, AND USE THEREOF | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2003-08-06 | — | — | EP | disclosed |
| US-20030087828-A1 | Peptide derivatives and pharmaceutically acceptable salts, thereof, processes for preparation of both, and use thereof | KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION (JP) | 2003-05-08 | — | — | US | disclosed |
| US-5763438-A | ANTIVIRAL AGENTS | SEIKAGAKU CORPORATION (JP) | 1998-06-09 | — | — | US | disclosed |
| EP-0765865-A1 | 2-ACYLAMINOPROPANOL COMPOUND AND MEDICINAL COMPOSITION | SEIKAGAKU CORPORATION (JP) | 1997-04-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230414613-A1 | PHARMACEUTICAL COMPOSITIONS | ABL1, ABCG2, LIPA | CHRNB2 4432/4885CHRNA4 4658/4885CHRNA3 4492/4885 |
| US-20030087828-A1 | Peptide derivatives and pharmaceutically acceptable salts, thereof, processes for preparation of both, and use thereof | NGLY1, DOHH, VIP | CHRNB2 4217/4885CHRNA4 4037/4885CHRNA3 3980/4885 |
| US-20170014468-A1 | METHODS OF USE FOR THERAPEUTICS TARGETING THE PATHOGEN PORPHYROMONAS GINGIVALIS | AGER, CD38, APP | CHRNB2 1285/4885CHRNA4 902/4885CHRNA3 1065/4885 |
| US-20170143716-A1 | METHOD OF TREATING PROLIFERATIVE DISORDERS AND OTHER PATHOLOGICAL CONDITIONS MEDIATED BY BCR-ABL, C-KIT, DDR1, DDR2 OR PDGF-R KINASE ACTIVITY | DDR2, DDR1, ABL2 | CHRNB2 1850/4885CHRNA4 3757/4885CHRNA3 3374/4885 |
| US-20060167015-A1 | 4-Methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-N-[5-(4-methyl-1H-imidazol1yl)-3-(trifluoromethyl)phenyl]benzamide or an N-oxide or salts; anticarcinogenic agent (leukaemia) | ABL1, CDK2, CDKN1A | CHRNB2 4307/4885CHRNA4 3815/4885CHRNA3 3849/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.